Urinary epidermal growth factor as a prognostic marker for the progression of Alport syndrome in children

Murine recombinant angiotensin-converting enzyme 2 attenuates kidney injury in experimental Alport syndrome

(2017) Eun Hui Bae et al.   KIDNEY INTERNATIONAL

Urinary peptidomics in a rodent model of diabetic nephropathy highlights epidermal growth factor as a biomarker for renal deterioration in patients with type 2 diabetes

(2016) Boris B. Betz et al.   KIDNEY INTERNATIONAL

X-Linked Hereditary Nephropathy in Navasota Dogs

(2016) S. L. Benali et al.   VETERINARY PATHOLOGY

Tissue transcriptome-driven identification of epidermal growth factor as a chronic kidney disease biomarker

(2015) Wenjun Ju et al.   Science Translational Medicine

Progression of Alport Kidney Disease in Col4a3 Knock Out Mice Is Independent of Sex or Macrophage Depletion by Clodronate Treatment

(2015) Munkyung Kim et al.   PLoS One

Anti–microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways

(2014) Ivan G. Gomez et al.   JOURNAL OF CLINICAL INVESTIGATION

Targeting CTGF, EGF and PDGF pathways to prevent progression of kidney disease

(2014) Helena M. Kok et al.   Nature Reviews Nephrology

Alport syndrome from bench to bedside: the potential of current treatment beyond RAAS blockade and the horizon of future therapies

(2014) O. Gross et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Metabolic syndrome loses its predictive power in late-stage chronic kidney disease progression – a paradoxical phenomenon

(2013) C.-C. Lee et al.   CLINICAL NEPHROLOGY

Milder clinical aspects of X-linked Alport syndrome in men positive for the collagen IV α5 chain

(2013) Yuya Hashimura et al.   KIDNEY INTERNATIONAL

Definitions of progression in chronic kidney disease—predictors and relationship to renal replacement therapy in a population cohort with a 6 year follow-up

(2013) Angharad Marks et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Updated height- and creatinine-based equation and its validation for estimation of glomerular filtration rate in children from developing countries

(2012) Pankaj Hari et al.   Clinical and Experimental Nephrology

Outcomes of Male Patients with Alport Syndrome Undergoing Renal Replacement Therapy

(2012) J. Temme et al.   Clinical Journal of the American Society of Nephrology

Urinary cystatin C as a biomarker for diabetic nephropathy and its immunohistochemical localization in kidney in Zucker diabetic fatty (ZDF) rats

(2012) Yuko Togashi et al.   EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY

Alport syndrome—insights from basic and clinical research

(2012) Jenny Kruegel et al.   Nature Reviews Nephrology

Chronic Kidney Disease Stage Progression in Liver Transplant Recipients

(2011) J. C. LaMattina et al.   Clinical Journal of the American Society of Nephrology

Interstitial inflammation in Alport syndrome

(2009) Jan Jedlicka et al.   HUMAN PATHOLOGY

Urinary levels of epidermal growth factor, interleukin-6 and monocyte chemoattractant protein-1 may act as predictor markers of renal function outcome in immunoglobulin A nephropathy

(2009) MARIA STANGOU et al.   NEPHROLOGY

Autosomal dominant Alport syndrome: molecular analysis of the COL4A4 gene and clinical outcome

(2009) Elena Marcocci et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION